



## Data collection at US Clinical Trial completed, analysis underway

**Perth, Australia & Malta – 8 January 2018** – Neurotech International Limited (ASX: NTI) (“Neurotech” or the “Company”), developer of quality medical solutions improving the lives of children with autism, is pleased to announce that the US Clinical Trial for its Mente Autism device has been completed and analysis is underway.

Principal Investigator for the Clinical Trial, Professor Frederick Carrick, advised that data collection for primary outcome measures for the neurofeedback study of Autism using the Mente Autism device (ClinicalTrials.gov ID: NCT02773303) has been completed and is duly noted at ClinicalTrials.gov, a resource provided by the U.S. National Library of Medicine. This is accessible at the following [link](#).

Preliminary findings of the Clinical Trial were presented at the 6<sup>th</sup> Cambridge International Conference on Mental Health Research 2017 held at Clare College, University of Cambridge, Cambridge, UK, held between 20 - 22 September 2017. As Professor Carrick noted, the preliminary findings ***“demonstrate[d] positive changes in children’s neurological function after using the Mente Autism device in our clinical study.”*** The full announcement can be accessed at the following [link](#).

Investigators from the Carrick Institute have commenced compiling and analysing the data from the study in preparation for submission of their findings for publication. The final results of the study will not be available to Neurotech or the public until the investigation has been published. As a fully independent study, Neurotech has had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Neurotech looks forward to updating the market once results are available to it.

-ends-

### About Neurotech

Neurotech International Limited is a medical device and solutions company incorporated in Australia and operating through its wholly-owned, Malta-based subsidiary AAT Research Limited. Neurotech’s primary mission is to improve the lives of people with neurological conditions, with a vision of becoming the global leader in home-use and clinical neurotechnology solutions that are both accessible and affordable. Through flagship device Mente Autism and its associated platform, Neurotech is focused on the development and commercialisation of technological solutions for the diagnosis and treatment of such conditions, starting with autism.

---

### Neurotech International Ltd

ABN 73 610 205 402

Level 14, 191 St Georges Terrace

Perth, Western Australia 6060

[www.neurotechinternational.com](http://www.neurotechinternational.com)

Mente Autism is a clinical-quality EEG device that uses neurofeedback technology to help children with ASD. Designed for home use, Mente Autism helps relax the minds of children on the spectrum which in turns helps them to focus better and engage positively with their environment.

For more information about Neurotech and Mente Autism please visit:

<http://www.neurotechinternational.com>.

<http://www.mentetech.com>.

*For more information please contact:*

Matthew Wright

[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)

Tel: +61 451 896 420